Neuropathic Pain Model Development Services
Ace Therapeutics is a specialized preclinical CRO dedicated to advancing analgesic drug discovery through robust in vivo model systems. Our neuropathic pain model development services provide a comprehensive platform for evaluating the efficacy, pharmacodynamics, and mechanisms of novel compounds targeting neuropathic pain—a chronic condition resulting from nerve injury or dysfunction.
Neuropathic pain arises from direct injury or disease affecting the somatosensory system. Unlike nociceptive pain, neuropathic pain is often spontaneous, persistent, and resistant to conventional treatments. Common clinical manifestations include mechanical allodynia, thermal hyperalgesia, and paresthesia.
We utilize species-specific models to mirror diverse etiologies. Each model undergoes stringent validation, including sham controls, baseline behavioral profiling, and histological confirmation.
| Model | Induction Method | Key Applications |
| Peripheral Nerve Injury Models | ||
| Chronic Constriction Injury (CCI) | Sciatic nerve ligation | Peripheral neuropathy, inflammatory pain |
| Spared Nerve Injury (SNI) | Tibial/peroneal nerve transection | Nerve trauma, tactile allodynia |
| Spinal Nerve Ligation (SNL) | L5/L6 nerve ligation | Radicular pain, central sensitization |
| Partial Sciatic Nerve Ligation (PSNL) | 33-50% sciatic nerve ligation | Mechanical hyperalgesia, neuroma formation |
| Dorsal Root Ganglion (DRG) Models | ||
| Chronic Compression of DRG (CCD) | L-shaped rod insertion in intervertebral foramen | Radicular pain, spontaneous activity |
| Dorsal Root Constriction (DRC) | L4/L5 dorsal root ligation | Compression neuropathy, axonal transport disruption |
| Partial Dorsal Rhizotomy (PDR) | L4-L6 dorsal root transection | Deafferentation pain, central reorganization |
| Central & Systemic Models | ||
| Spinal Cord Injury (SCI) | T10-T12 spinal contusion | Central neuropathic pain, below-level pain |
| Multiple Sclerosis (EAE model) | MOG35-55 immunization | Demyelination-associated pain |
| Diabetic Neuropathy | Streptozotocin injection | Metabolic pain, small fiber neuropathy |
| Chemotherapy-Induced (Paclitaxel) | Paclitaxel (2-4 mg/kg cumulative) | CIPN, mitochondrial dysfunction |
| HIV-Associated Neuropathy | Intrathecal gp120 injection | Viral neuropathy, glial activation |
| Local Inflammatory Dorsopathy (LID) | CFA/carrageenan epidural injection | Inflammatory radiculopathy |
We provide multi-layered endpoint evaluation to deliver translational insights across behavioral, histological, molecular, and functional domains.
Behavioral Assessments
Molecular and Cellular Analysis
Histopathology
Electrophysiology
PK/PD and Toxicology Support
Ace Therapeutics is your trusted CRO partner for advancing neuropathic pain therapeutics. From model development to mechanistic exploration, we provide integrated preclinical services that support evidence-based drug development decisions.
How do I select the most appropriate neuropathic pain model for my compound?
We offer complimentary consultations to help you align model selection with your drug's mechanism of action and target indication. Factors such as symptom profile, route of administration, and translational relevance are considered.
Can you accommodate custom endpoints beyond your standard panel?
Yes, we can integrate novel biomarkers, imaging modalities, or behavioral paradigms based on your research needs and target pathway.
What types of compounds can be tested using your models?
Our platform supports a wide range of modalities, including small molecules, peptides, monoclonal antibodies, and gene therapies.
Do you offer combination therapy testing?
Yes, we can design studies that evaluate synergistic or additive effects of combination therapies in relevant models.
Are your models validated with known reference compounds?
Each model undergoes pharmacological validation using reference analgesics to ensure consistency and responsiveness.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics comprises a team of highly committed and skilled researchers focused exclusively on providing innovative preclinical contract research solutions for novel analgesic development. We deliver rigorous models and data essential for advancing targeted, non-addictive pain therapies toward clinical evaluation.